Inovio Pharmaceuticals, Inc.

INO · Nasdaq · United States

Share price · INO

$1.69+0.49 (+40.83%) 3M

close as of 2026-11-18 · 24h delayed · vol 11.6M (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when INO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026+213.7%
  2. 30 Oct 2026-21.9%
  3. 29 Oct 2026-16.9%

    Nothing announced by INO that day or the session before.

  4. 21 Oct 2026-21.3%
  5. 14 Aug 2026+21.1%

    Nothing announced by INO that day or the session before.

  6. 13 Aug 2026+16.9%
  7. 30 Jul 2026-36.9%
  8. 1 Jul 2026+8.2%

    Nothing announced by INO that day or the session before.

  9. 7 May 2026+10.5%

    Nothing announced by INO that day or the session before.

  10. 2 Apr 2026-35.1%

Share of unusual movement by asset

For each asset, the share of INO's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
INO-3107 (Voceryq)
events and moves
5shown from 8 days
Assets with fewer than 8 event days, together—83%
Other company news (earnings, financing, releases naming no asset)—9%
Sessions with no dated event—8%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
INO-3107(Voceryq)
Approved
HPV-6 and HPV-11 antigensGene therapy / editing
Recurrent Respiratory Papillomatosis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 November 2026Filing submittedINO-3107Conditional MAA submitted to EMA for VOCERYQ
EU, EMA · Source ↗
30 October 2026FDA action dateINO-3107PDUFA goal date for the INO-3107 BLA in RRP
US, FDA · FDA · Source ↗
30 October 2026ApprovalINO-3107FDA grants accelerated approval to Voceryq (INO-3107) in RRP
US, FDA · Source ↗
29 December 2025Filing acceptedINO-3107FDA accepts INOVIO's BLA for INO-3107 in adults with RRP (standard review, accelerated approval pathway)
US, FDA · Inovio Pharmaceuticals, Inc. · Source ↗
3 November 2025Filing submittedINO-3107INOVIO completes the rolling BLA submission for INO-3107 (accelerated approval)
US, FDA · Inovio Pharmaceuticals, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.3M$11M$47M+ $1.4M short-term inv.$49M-$15M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$11M$32M+ $5.2M short-term inv.$6.0M-$18M operating cash flowreport ↗
2026-Q1$0$14M$26M+ $11M short-term inv.$20M-$22M operating cash flowreport ↗
2025-Q3$0$13M$37M+ $14M short-term inv.$46M-$22M operating cash flowreport ↗
2025-Q2$0$15M$24M+ $23M short-term inv.$24M-$21M operating cash flowreport ↗
2025-Q1$0.1M$16M$40M+ $28M short-term inv.$20M-$27M operating cash flowreport ↗
2024-Q3$0$19M$22M+ $63M short-term inv.$25M-$27M operating cash flowreport ↗
2024-Q2$0.1M$23M$34M+ $76M short-term inv.$32M-$28M operating cash flowreport ↗
2024-Q1$0$21M$20M+ $86M short-term inv.$30M-$29M operating cash flowreport ↗
2023-Q3$0.4M$16M$19M+ $149M short-term inv.$34M-$29M operating cash flowreport ↗
2023-Q2$0.2M$24M$53M+ $142M short-term inv.$36M-$32M operating cash flowreport ↗
2023-Q1$0.1M$30M$28M+ $196M short-term inv.$41M-$37M operating cash flowreport ↗
2022-Q3$9.2M$33M$22M+ $260M short-term inv.$38M-$67M operating cash flowreport ↗
2022-Q2$0.8M$56M$41M+ $307M short-term inv.$109M-$51M operating cash flowreport ↗
2022-Q1$0.2M$56M$59M+ $301M short-term inv.$79M-$62M operating cash flowreport ↗
2021-Q3$0.3M$47M$68M+ $327M short-term inv.$60M-$46M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.1M$54M$44M+ $14M short-term inv.$21M-$89M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.2M$76M$66M+ $28M short-term inv.$27M-$104M operating cash flowreport ↗
2023-FY$0.8M$87M$14M+ $131M short-term inv.$34M-$124M operating cash flowreport ↗
2022-FY$10M$188M$46M+ $207M short-term inv.$70M-$216M operating cash flowreport ↗
2021-FY$1.8M$249M$71M+ $330M short-term inv.$76M-$216M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-05-20Shea Jacqueline Elizabeth · director, Chief Executive OfficerOption exercise28,296——Form 4
2026-05-20KIES PETER · CFOOption exercise8,700——Form 4
2026-05-20Sumner Michael John · Chief Medical OfficerOption exercise9,450——Form 4
2026-05-20Humeau Laurent · Chief Scientific OfficerOption exercise6,027——Form 4
2026-05-20BENITO SIMON X · directorAward / grant (derivative)41,800——Form 4
2026-05-20DANSEY ROGER D · directorAward / grant (derivative)41,800——Form 4
2026-05-20Zoth Lota S. · directorAward / grant (derivative)41,800——Form 4
2026-05-20Weiner David B. · directorAward / grant (derivative)41,800——Form 4